Pcsk9 Inhibitors | List of Frontiers open access articles

Review

Published on 03 Sep 2025

Which is the optimal choice in lipid-lowering therapy for reducing major cardiovascular events? a network meta-analysis

in Cardiovascular and Smooth Muscle Pharmacology

Qiang Niu
Qilei Wang
Feng Chen
Bo Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1626681

3,743 views

Review

Published on 25 Jun 2024

PCSK9 inhibition: from effectiveness to cost-effectiveness

in Lipids in Cardiovascular Disease

Iveta Mercep
Dominik Strikic
Pero Hrabac
Ivan Pecin
Željko Reiner

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1339487

7,324 views
24 citations

Original Research

Published on 01 Aug 2024

Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study

in Renal Pharmacology

Hailing Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1353848

7,922 views
5 citations

Review

Published on 02 May 2023

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation

in Lipids in Cardiovascular Disease

Hongzhen Chen
Xiaomin Chen

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1138787

14,542 views
32 citations

Original Research

Published on 29 Nov 2023

A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022

in Cardiovascular Endocrinology

Qin Luo
Zhenchu Tang
Panyun Wu
Zhangling Chen
Zhenfei Fang
Fei Luo

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1218968

5,387 views
5 citations

Review

Published on 08 Dec 2022

Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome

in Coronary Artery Disease

F. B. Mensink
J. Los
T. J. F. Ten Cate
R. M. Oemrawsingh
M. A. Brouwer
S. El Messaoudi
N. van Royen
J. H. Cornel
N. P. Riksen
R. J. M. van Geuns

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.1061346

5,848 views
7 citations

Systematic Review

Published on 25 Sep 2024

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis

in Cardiovascular Pharmacology and Drug Discovery

Dong Liu
Jin Zhang
Xiaoyu Zhang
Fengli Jiang
Yiping Wu
Beibei Yang
Xinghuan Li
Xiongxiong Fan
Han Li
Yu Sun

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1454918

6,349 views
2 citations

Systematic Review

Published on 02 Dec 2022

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

in Atherosclerosis and Vascular Medicine

Hong-Fei Wang
Yu-Cheng Mao
Xin-Yi Xu
Si-Yu Zhao
Dan-Dan Han
Shi-Yao Ge
Kai Song
Chang Geng
Qing-Bao Tian

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.1016802

14,267 views
13 citations

Mini Review

Published on 11 Jan 2024

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke

in Cardiovascular and Smooth Muscle Pharmacology

Lin Zhou
Hongyu Zhang
Shuyi Wang
Hong Zhao
Yongnan Li
Juqian Han
Hongxu Zhang
Xiaoyuan Li
Zhengyi Qu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1327185

5,985 views
4 citations

Original Research

Published on 04 Apr 2022

Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis

in Cardiovascular and Smooth Muscle Pharmacology

Yi-Ting Huang
Li-Ting Ho
Hsin-Yin Hsu
Yu-Kang Tu
Kuo-Liong Chien

Frontiers in Pharmacology

doi 10.3389/fphar.2022.832614

8,826 views
16 citations

Case Report

Published on 22 Sep 2025

PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report

in Lipids in Cardiovascular Disease

Yuan Li
Huiyan Jiang
Yajuan Xiong
Simin Yan
Xin Chen

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2025.1644145

2,715 views

Original Research

Published on 06 Mar 2026

Integrating pharmacovigilance signals with real-world validation: a study on neurological events associated with PCSK9 inhibitors

in Translational Medicine

Bing Zhu
Qiqi Shao
Jun Cui
Zhenyan Fu
Yitong Ma

Frontiers in Medicine

doi 10.3389/fmed.2026.1765715

Review

Published on 23 Sep 2024

Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease

in Precision Medicine

Tatjana Ábel
Béla Benczúr
Éva Csajbókné Csobod

Frontiers in Medicine

doi 10.3389/fmed.2024.1458025

3,739 views
5 citations

Original Research

Published on 18 Dec 2025

Differential effects of PCSK9 inhibitors and statins on plasma ceramides in coronary artery disease

in Cardiovascular and Smooth Muscle Pharmacology

Liang Zhang
Yaodong Ding
Yong Zeng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1726925

1,199 views

Original Research

Published on 05 Mar 2026

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes

in Hepatobiliary Diseases

Qingna Zhou
Xiaoxia Liu
Yunzhao Tang
Congqing Pan
Xuena Bi

Frontiers in Medicine

doi 10.3389/fmed.2026.1756998

Original Research

Published on 19 Nov 2025

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective

in Drugs Outcomes Research and Policies

Dandan Hu
Xu Deng
Mengwen Feng
Xinyue Zhang
Qingfeng He
Tao Wang
Zhen Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1708701

2,449 views

Articles

Which is the optimal choice in lipid-lowering therapy for reducing major cardiovascular events? a network meta-analysis

PCSK9 inhibition: from effectiveness to cost-effectiveness

Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation

A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022

Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke

Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis

PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report

Integrating pharmacovigilance signals with real-world validation: a study on neurological events associated with PCSK9 inhibitors

Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease

Differential effects of PCSK9 inhibitors and statins on plasma ceramides in coronary artery disease

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective